January 5, 2022

Jim Carey

Jim Carey is the CEO of JP Carey Consulting LLC, which provides comprehensive strategic consulting services on federal and state public policy and marketplace issues relevant to its clients. 

Previously, Jim was Head of U.S. Policy and Government Affairs for Organon and Co., a global healthcare company, formed through a spinoff from Merck in June 2021, with a mission to deliver impactful medicines and solutions for a healthier every day. Organon’s vision is “A better and healthier every day for every woman.” In that role at Organon, Jim led federal and state policy and government relations and served on the leadership team for Organon’s External Affairs and ESG group.

Jim also serves as the Treasurer of The Biosimilars Forum, an organization founded to inform and support public policies that encourage awareness, access, and adoption of biosimilars in the United States. During his 7 years with Merck in U.S. Federal Policy in Washington, DC, Jim served as policy lead for Merck’s U.S. Biosimilars, Diabetes, Hepatitis, and HIV businesses. Prior to joining Merck in 2014, Jim was Vice President and Head of U.S. Corporate Policy for Novartis Corporation, also based in Washington, DC. His responsibilities included directing the Public Policy agenda for the Novartis Group Companies in the U.S., ensuring coordination and collaboration across all U.S. business units.

Jim has more than three decades of experience in pharmaceutical industry federal and state public policy. A native of Scranton, PA, Jim and his wife Cathy live in Alexandria, VA and have three adult children, Alison, Jackie, and Chris.